Reviewer’s report

Title: BEV-IP: Perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis

Version: 1 Date: 10 Oct 2015

Reviewer: Randall Holcombe

Reviewer’s report:

This is an interesting protocol looking at the utility and safety of bevacizumab peri-operatively for patients with peritoneal carcinomatosis from colorectal cancer.

The study protocol is well described and straightforward. Statistics are acceptable.

However, one revision is essential. The primary study outcome is assessment of morbidity and mortality following the cytoreductive surgery and preoperative chemotherapy. However, while some statistics are provided regarding "morbidity", what is being measured and assessed as morbidity is not defined anywhere in the protocol. This must be included. Everyone getting chemotherapy and extensive surgery has some degree of morbidity. What is being recorded for the protocol must be detailed very specifically. If it cannot, than morbidity cannot be utilized as an outcome. In the latter circumstance, if mortality is the only outcome, then the sample size would need to be drastically increased.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Unable to assess

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Unable to assess

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics
Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal